EVEREST STUDY: Efficacy and Safety of Verteporfin Photodynamic Therapy in Combination with Ranibizumab or Alone Versus Ranibizumab Monotherapy in Patients with Symptomatic Macular Polypoidal Choroidal Vasculopathy
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
In Brief Purpose: To assess the effects of verteporfin photodynamic therapy (PDT) combined with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Methods: In this multicenter, double-masked, primarily indocyanine green angiography–guided trial, 61 Asian patients were randomized to verteporfin PDT (standard fluence), ranibizumab 0.5 mg, or the combination. Patients were administered with verteporfin PDT/placebo and initiated with three consecutive monthly ranibizumab/sham injections starting Day 1, and re-treated (Months 3–5) as per predefined criteria. The primary endpoint was the proportion of patients with indocyanine green angiography–assessed complete regression of polyps at Month 6. Secondary endpoints included mean change in best-corrected visual acuity at Month 6 and safety. Results: At Month 6, verteporfin combined with ranibizumab or alone was superior to ranibizumab monotherapy in achieving complete polyp regression (77.8% and 71.4% vs. 28.6%; P < 0.01); mean change ± standard deviation in best-corrected visual acuity (letters) was 10.9 ± 10.9 (verteporfin PDT + ranibizumab), 7.5 ± 10.6 (verteporfin PDT), and 9.2 ± 12.4 (ranibizumab). There were no new safety findings with either drug used alone or in combination. Conclusion: Verteporfin PDT combined with ranibizumab 0.5 mg or alone was superior to ranibizumab monotherapy in achieving complete regression of polyps in this 6-month study in patients with symptomatic macular polypoidal choroidal vasculopathy. All treatments were well tolerated over 6 months. EVEREST, the first, multicenter, double-masked, primarily indocyanine green angiography–guided randomized controlled trial for symptomatic macular polypoidal choroidal vasculopathy, demonstrated superiority of verteporfin photodynamic therapy combined with ranibizumab or alone over ranibizumab monotherapy in achieving complete regression of polyps at Month 6. Best-corrected visual acuity improved in all treatment arms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the United Kingdom, ICGA is not available in all units and is usually reserved for cases presenting with clinical features suspicious of polypoidal choroidopathy (IPCV) or retinal angiomatous proliferation (RAP) or when response to anti-VEGF therapy is suboptimal.11,12”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
In the citing paper
“Some lesion types are thought to be less responsive than others to anti-VEGF therapy, for example, IPCV.”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
In the citing paper
“The EVEREST study suggested that combination therapy of IPCV with photodynamic therapy (PDT) and ranibizumab led to a better outcome than monotherapy with ranibizumab.11,12”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
In the citing paper
“However, an expanding or increased elevation in PED indicates activity that merits evaluation and treatment.11,12”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
Citations
Cites
Chung, S. E., Kang, S. W., Lee, J. H., & Kim, Y. T. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.09.012 · Cited by 580
Polypoidal Choroidal Vasculopathy: Incidence, Demographic Features, and Clinical Characteristics
Sho, K. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.10.1392 · Cited by 439 · cited 1×
“Moreover, the incidence of sub-RPE hemorrhage or subretinal hemorrhage in patients with PCV is high (30%–64%).(3,9) In a study of the natural history of patients with PCV, Uyama et al(6) reported that half of the study eyes had hemorrhagic episodes, recurrent leakage, or severe RPE atrophy after a long follow-up perio…”
BackgroundThe Expanding Clinical Spectrum of Idiopathic Polypoidal Choroidal Vasculopathy
Yannuzzi, L. A. (1997) · Archives of Ophthalmology · doi:10.1001/archopht.1997.01100150480005 · Cited by 436 · cited 3×
“It may be associated with a branching vascular network (BVN) and clinically visible orange-red subretinal nodule(s).(1) Polypoidal choroidal vasculopathy is prevalent in 10% to 54% of the Asian patients and in 8% to 12% of white patients with presumed exudative age-related macular degeneration (AMD).”
BackgroundPolypoidal choroidal vasculopathy: natural history
Uyama, M., Wada, M., Nagai, Y., Matsubara, T., Matsunaga, H., Fukushima, I., Takahashi, K., & Matsumura, M. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01404-6 · Cited by 402 · cited 3×
“In PCV, the polypoidal lesions originate from the inner choroidal vasculature and can progress beneath the RPE.(1,6,7) The presence of orange-red nodule–like structures beneath the RPE associated with an adjacent serous pigment epithelial detachment or overlying neurosensory detachment, subretinal hemorrhage, and lipi…”
BackgroundTong, J.-P., Chan, W.-M., Liu, D. T. L., Lai, T. Y. Y., Choy, K.-W., Pang, C.-P., & Lam, D. S. C. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.10.012 · Cited by 385 · cited 1×
“The increased expression of VEGF in the aqueous humor of eyes with PCV provides a biologic rationale for treatment with anti-VEGF agents.(19) Limited data from case series with bevacizumab monotherapy have shown that treatment may reduce leakage associated with PCV but is ineffective for complete regression of the pol…”
BackgroundSelf-citationPhotodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy
Chan, W.-M., Lam, D. S. C., Lai, T. Y. Y., Liu, D. T. L., Li, K. K. W., Yao, Y., & Wong, T.-H. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2003.12.056 · Cited by 283
Self-citation(2003) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(03)00223-x · Cited by 274 · cited 1×
“For CNV secondary to AMD, the Verteporfin In Photodynamic Therapy and the Treatment of AMD with Photodynamic Therapy study has demonstrated that there was gradual visual deterioration or no visual improvement with high re-treatment rate at 6 months for treated patients after verteporfin PDT administration.(25) This tr…”
ResultEfficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy
Gomi, F., Sawa, M., Sakaguchi, H., Tsujikawa, M., Oshima, Y., Kamei, M., & Tano, Y. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.122283 · Cited by 242 · cited 1×
“These findings are consistent with those reported earlier with other anti-VEGF therapies.(20,21)”
ResultGomi, F., Ohji, M., Sayanagi, K., Sawa, M., Sakaguchi, H., Oshima, Y., Ikuno, Y., & Tano, Y. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.02.031 · Cited by 239
The origins of polypoidal choroidal vasculopathy
Yuzawa, M. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2004.049296 · Cited by 198 · cited 4×
“Use of dynamic confocal scanning laser ophthalmoscope–ICGA may assist in further elucidating the BVN, from which these focal evaginating nodules arise, enabling clearer definition and differentiation from exudative AMD because of CNV.(7) Based on ICGA findings, PCV is defined as the presence of single or multiple foca…”
BackgroundInfluential
Cited by
Items 301–400 of 586
Zhao, M., Zhou, H.-Y., Xu, J., Zhang, F., Wei, W., & Liu, N. (2017) · International Journal of Ophthalmology · doi:10.18240/ijo.2017.03.14 · Cited by 12
Azuma, K., Asaoka, R., Matsuda, A., Lee, J., Shimizu, K., Inui, H., Murata, H., Ogawa, A., Yamamoto, M., Inoue, T., et al. (2018) · Clinical ophthalmology · doi:10.2147/opth.s172115 · Cited by 11
“Similar to previous reports, 34–37 CVH was defined as the presence within the choroid of multifocal areas of hyperfluorescence with blurred margins identified in the late phase of ICGA.”
InfluentialApplications of Multimodal Imaging in Central Serous Chorioretinopathy Evaluation
Ho, M., Li, G. E., Mak, A. C. Y., Ng, D. S., Iu, L. P. L., & Lai, F. H. P. (2021) · Journal of Ophthalmology · doi:10.1155/2021/9929864 · Cited by 9
“In both EVEREST criteria [8] and Japanese Study Group guideline [9], ICGA is the gold-standard investigation to diagnose PCV.”
InfluentialChang, Y. S., Kim, J. H., Kim, J. W., Lee, T. G., Kim, C. G., & Cho, S. W. (2015) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-015-3173-1 · Cited by 9
Clinical outcomes in Caucasian patients with polypoidal choroidal vasculopathy
Agorogiannis, E. I., Pearce, I. A., Yadav, S., Parry, D., & Beare, N. A. V. (2018) · Eye · doi:10.1038/s41433-018-0168-2 · Cited by 9
Sax, J., Karpa, M., & Reddie, I. C. (2018) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000000787 · Cited by 9
Zhan, Z., Sun, L., Jin, C., Yu, Y., Hu, A., Tang, M., Wang, Z., & Ding, X. (2019) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-019-04445-5 · Cited by 9
Lindeke-Myers, A. T., Kokame, G. T., Yeh, S., & Shantha, J. G. (2020) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126420909706 · Cited by 9
Intravitreal Injection with a Conjunctival Injection Device: A Single-Center Experience
Soh, Y. Q., Chiam, N., Tsai, A. S. H., Cheung, C. M. G., Wong, T. Y., Yeo, I. Y. S., Wong, E. Y., & Tan, A. C. S. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.8.28 · Cited by 9
Serra, R., Coscas, F., Cabral, D., Pinna, A., & COSCAS, G. J. (2022) · Retina · doi:10.1097/iae.0000000000003439 · Cited by 9
Ho, M., Woo, D. C. F., Chan, V. C. K., Young, A. L., & Brelen, M. E. (2016) · Scientific Reports · doi:10.1038/srep36870 · Cited by 9
Han, L., Yuan, L., Liang, X., Jia1, X., & Zhang, M. (2017) · International Journal of Ophthalmology · doi:10.18240/ijo.2017.08.16 · Cited by 9
Kanadani, T. C. M., Veloso, C. E. D. R., & Nehemy, M. B. (2018) · Ophthalmologica · doi:10.1159/000488254 · Cited by 9
Polypoidal choroidal vasculopathy in Canada
Lam, W., Choudhry, N., & Wong, D. T. (2019) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2019.10.011 · Cited by 9
Choi, S., Kang, H. M., & Koh, H. J. (2020) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-020-04924-0 · Cited by 9
Park, U. C., Kim, B. H., Choe, H. R., Yeon, D. Y., & Yu, H. G. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14719 · Cited by 10
“…in polypoidal choroidal vasculopathy (PCV), which is an unique variant of type 1 neovascularization, PDT is still an effective therapeutic option resulting in vision improvement and polyp regression, while requiring less anti-VEGF injections (Koh et al. 2012; Koh et al. 2017; Lee et al. 2018).”
BackgroundAflibercept for the treatment of refractory polypoidal choroidal vasculopathy
Yonekawa, Y. (2013) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2012.12.015 · Cited by 8
Byon, I. S., Kwon, H. J., Kim, S. I., Shin, M. K., Park, S. W., & Lee, J. E. (2014) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20141118-08 · Cited by 8
Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences
Ratanasukon, M., Bhurayanontachai, P., & Jirarattanasopa, P. (2018) · Clinical ophthalmology · doi:10.2147/opth.s178228 · Cited by 8
“Diagnosis of PCV followed the diagnostic criteria of the EVEREST study, 2 and the diagnostic agreement of at least two of the three specialists was required.”
Polypoidal Choroidal Vasculopathy
Goldhardt, R., & Rosen, B. S. (2019) · Current Ophthalmology Reports · doi:10.1007/s40135-019-00201-4 · Cited by 9
Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
Lee, S. E., Jang, J. W., Kang, S. W., Park, K. H., Lee, D. W., Kim, J. H., & Bae, K. (2019) · Scientific Reports · doi:10.1038/s41598-018-37523-5 · Cited by 8
Current diagnosis and management strategies in pachychoroid spectrum of diseases (Review)
Moraru, A. D., Costin, D., Moraru, R., Costuleanu, M., & Brănişteanu, D. C. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9094 · Cited by 8
Chi, S.-C., Kang, Y., & Huang, Y.-M. (2021) · Scientific Reports · doi:10.1038/s41598-021-82316-y · Cited by 8
Marcus, D. M., Singh, H., Fechter, C., & Chamberlain, D. (2015) · Eye · doi:10.1038/eye.2015.150 · Cited by 8
Radiating hemorrhage in exudative age-related macular degeneration
Kim, J. H., Chang, Y. S., Kim, J. W., Lee, T. G., Kim, C. G., & Lee, D. W. (2016) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-016-0466-9 · Cited by 8
“Thus, photodynamic therapy, which is found to be less efficient for the treatment of exudative AMD than anti-VEGF therapy [24], is still used as a treatment option in PCV [20, 22, 25].”
BackgroundTan, C. S., Lim, L. W., & Hariprasad, S. M. (2018) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20171215-01 · Cited by 8
Lai, K., Zhou, L., Zhong, X., Huang, C., Gong, Y., Xu, F., Ma, L., Chen, G., Cheng, L. Z., Lin, L., et al. (2018) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20181002-13 · Cited by 8
Novel Findings of Polypoidal Choroidal Vasculopathy via Optical Coherence Tomography Angiography
Seong, S., Choo, H. G., Kim, Y. J., Kim, J., Lee, J. H., Oh, H. S., You, Y. S., Kim, S. H., & Kwon, O. W. (2018) · Korean Journal of Ophthalmology · doi:10.3341/kjo.2018.0048 · Cited by 10
Yeung, L., Lai, C., Chen, S., Cheng, C., Yang, C., Hsieh, Y., Tsai, A., & Yang, C. (2021) · Scientific Reports · doi:10.1038/s41598-020-80731-1 · Cited by 8
Self-citationKim, H., Lee, J. H., Kwon, K. Y., Byeon, S. H., Lee, S. C., & Lee, C. S. (2015) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20150422-04 · Cited by 8
Self-citationChong, Y. J., Teo, K. Y. C., Wong, W., Tan, A. C. S., Su, X., Gilead, N., Chan, H. H., Ibrahim, F. N. I. M., Fenner, B. J., Ong, C., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.0250 · Cited by 9
The Clinical Spectrum of Polypoidal Choroidal Vasculopathy in White Patients
Sirks, M. J., van Dijk, E. H. C., Ghalayini, H., Bazdar, S., Yu, W., Yzer, S., Ciriano, J. P. M., Schlingemann, R. O., Diederen, R. M. H., & Boon, C. J. F. (2025) · Ophthalmology Retina · doi:10.1016/j.oret.2025.04.019 · Cited by 8
Cho, J., Han, H. Y., Park, S. M., Kim, J. H., & Cho, H. J. (2025) · Eye · doi:10.1038/s41433-025-03980-2 · Cited by 9
Chaikitmongkol, V., Ozimek, M. A., Srisomboon, T., Patikulsila, D., Fraser‐Bell, S., Chhablani, J. K., Choovuthayakorn, J., Watanachai, N., Kunavisarut, P., Rodríguez‐Valdés, P. J., et al. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.07.024 · Cited by 7
Hatamnejad, A., Patil, N. S., Mihalache, A., Popovic, M. M., Kertes, P. J., Muni, R. H., & Wong, D. T. (2023) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2023.04.002 · Cited by 7
Singh, S. R., Goyal, P., Parameswarappa, D. C., Goud, A., & Chhablani, J. K. (2019) · European Journal of Ophthalmology · doi:10.1177/1120672119850075 · Cited by 7
Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
Gu, X., Yu, X., & Dai, H. (2019) · BMC Ophthalmology · doi:10.1186/s12886-019-1156-4 · Cited by 7
“Two randomized clinical trials (EVEREST and LAPTOP) reported that ranibizumab was more effective in improving VA than PDT [14, 15].”
BackgroundResultSumnicht, A., Chalam, K. V., Alset, A. E., & Sierpina, D. I. (2021) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2021.102390 · Cited by 7
PREDICTORS AND IMPORTANCE OF COMPLETE POLYPOIDAL LESION REGRESSION IN THE EVEREST II STUDY
Tan, C. S., Cheung, C. M. G., Lai, T. Y. Y., Pataluskaite, R., Margaron, P., & Lim, T. H. (2022) · Retina · doi:10.1097/iae.0000000000003595 · Cited by 7
Self-citationSumnicht, A., Chalam, K. V., & Sierpina, D. I. (2022) · Clinical ophthalmology · doi:10.2147/opth.s359302 · Cited by 8
“Combination therapy was evaluated in the EVEREST I and EVEREST II studies, which demonstrated a superior response to PRN intravitreal ranibizumab in combination with PDT compared to PRN ranibizumab alone in terms of both polyp regression, as well as visual acuity.(14,22) In contrast, there was an 85% rate of improved…”
MethodLi, X., Qu, J., Su, G., Yu, S., Zhang, Y., Sadda, S. V. R., & STAR Study Group (2022) · Acta Ophthalmologica · doi:10.1111/aos.15272 · Cited by 7
“…monotherapy has superseded PDT as the first line therapy for nAMD and has also been shown to have favourable visual outcomes for active PCV (Cheung et al., 2017; Koh et al., 2012; Koh et al. 2020; Lee et al., 2018; Lim et al., 2020; Miyamoto et al., 2019; Ogura et al., 2021; Wong et al., 2019).”
BackgroundInfluentialLin, W.-Y., Yang, S.-C., Chen, S., Tsai, C.-L., Du, S.-Z., & Lim, T.-H. (2015) · Translational Vision Science & Technology · doi:10.1167/tvst.4.2.7 · Cited by 7
Self-citationOtsuji, T., Sho, K., Koike, N., Tsumura, A., Nishimura, T., & Takahashi, K. A. (2016) · Clinical ophthalmology · doi:10.2147/opth.s102171 · Cited by 7
“PDT has reduced the risk of vision loss for AMD patients with subfoveal CNV. PDT is considered to be effective, especially for PCV. Data from the EVEREST study showed that PDT combined with intravitreal ranibizumab (IVR) or alone was superior to IVR monotherapy in achieving complete regression of polyps in patients wi…”
Marques, J. P., Farinha, C., Costa, M. A., Ferrão, Â., Nunes, S. G., & da Silva, R. M. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015785 · Cited by 8
Liang, S., Shi, X., Rosenfeld, P. J., & Li, X. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2017-311518 · Cited by 7
Yoshida, I., Sakamoto, M., Sakai, A., & Maeno, T. (2020) · Journal of Ophthalmology · doi:10.1155/2020/5308597 · Cited by 6
Flow signal change in polyps after anti-vascular endothelial growth factor therapy
Chang, C.-J., Huang, Y.-M., Hsieh, M., Li, A.-F., & Chen, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241230 · Cited by 7
Self-citationZhao, X., Zhang, W., Meng, L., Wang, D., & Chen, Y. (2020) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-020-04977-1 · Cited by 8
“All these made the ophthalmologists hard to explain the course of PCV to their patients; precise estimates of the rates of these indices were urgently needed to help the clinicians understand the very nature of PCV; (3) Some previous randomized controlled trials (RCTs) like EVEREST II study suggested that the combinat…”
BackgroundChay, J., Fenner, B. J., Finkelstein, E. A., Teo, K. Y. C., & Cheung, C. M. G. (2021) · Eye · doi:10.1038/s41433-021-01856-9 · Cited by 7
“As such, both anti-VEGF monotherapy and initial combination therapy with verteporfin photodynamic therapy (PDT) are currently accepted as standards of care [6, 8, 10, 11].”
BackgroundResultEmerging biological therapies for the treatment of age-related macular degeneration
Asahi, M., Avaylon, J., Wallsh, J. O., & Gallemore, R. P. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1931120 · Cited by 8
Five‐year follow‐up results of photodynamic therapy for polypoidal choroidal vasculopathy
KANG, H., & KOH, H. (2012) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2012.s052.x · Cited by 7
Zhang, W., Gu, X., Li, B., Liu, S., Jingyuan, Y., Wang, Y., Cheng, S., Lv, L., Li, Z., Lu, L., et al. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2393273 · Cited by 6
“inclusion criteria were: (1) treatment naive PcV diagnosed according to eVeRest criteria [20], namely focal hyperfluorescent lesions appearing in first 6 min with or without BNN on indocyanine green angiograph (icGa); or non-icGa diagnostic criteria from the asia-Pacific Ocular imaging society PcV…”
MethodHoshino, J., Matsumoto, H., Nakamura, K., & Akiyama, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-51628-0 · Cited by 6
“The regression rates of polypoidal lesions evaluated by ICGA are reportedly about 30% for intravitreal ranibizumab (IVR) 24,25 , approximately 50% for IVA 20,26 , and 70–90% for combination therapy with PDT and IVR or IVA 24,25,27 , while approaching 80% for IVBr 21,28,29 .”
BackgroundKim, D. J., Kim, D. G., Kwak, H. D., Jang, J. Y., Ji, Y., Lee, S. H., Lee, E. K., Park, K. H., Kim, J. H., Lee, J. S., et al. (2024) · Acta Ophthalmologica · doi:10.1111/aos.16699 · Cited by 8
“The changes were established according to polyp regression observed on ICGA: (1) complete regression: no polyps observed on ICGA: (2) partial regression: > 10% decrease in polyp area compared with baseline; and (3) no response: ≤10% change of polyp area compared with baseline (Koh et al., 2012).”
Ma, Y., Rao, S., Tan, Y., Du, H., & Sun, X. (2024) · BMC Ophthalmology · doi:10.1186/s12886-024-03660-x · Cited by 7
“Submacular hemorrhage (SMH) is a severe, vision-threatening condition with multiple potential causes [1– 5].”
BackgroundChoroidal Watershed Zone and Growth of Polypoidal Choroidal Vasculopathy
Shin, M. K., Lee, J. E., Byon, I. S., & Park, S. W. (2016) · Current Eye Research · doi:10.1080/02713683.2016.1183794 · Cited by 6
Age-related macular degeneration masqueraders: From the obvious to the obscure
Paez-Escamilla, M. A., Jhingan, M., Gallagher, D. S., Singh, S. R., Fraser‐Bell, S., & Chhablani, J. K. (2020) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2020.08.005 · Cited by 7
Lim, L. W., Tan, C. S., & Ting, D. S. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.2.35 · Cited by 6
The Contemporary Role of Photodynamic Therapy in the Treatment of Pachychoroid Diseases
Iu, L. P. L., Chan, H. Y., Ho, M., Lai, F. H. P., Mak, A. C. Y., Wong, R. L. M., & Young, A. L. (2021) · Journal of Ophthalmology · doi:10.1155/2021/6590230 · Cited by 6
“In the EVEREST I study [45], 61 patients were randomized in a 1 :1:1 ratio to receive PDT monotherapy, PDT combined with monthly ranibizumab, or monthly ranibi-zumab monotherapy.”
Chen, L., Yuan, M., Sun, L., & Chen, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030742 · Cited by 6
“The inclusion crite‐ ria were as follows: (1) eyes with the clinical diagnosis of PCV by two independent retinal specialists based on the ICGA criteria used in the EVEREST study [29], and (2) treatment‐ naïve PCV eyes.”
MethodSelf-citationKato, A., Yasukawa, T., Suga, K., Hirano, Y., Nozaki, M., Yoshida, M., & Ogura, Y. (2014) · Ophthalmologica · doi:10.1159/000368249 · Cited by 6
Fernandez, M. B., Gil, M., Gómez‐Ulla, F., & Charlón, P. (2012) · Case Reports in Medicine · doi:10.1155/2012/897097 · Cited by 6
“The Everest Study showed that the disappearance rate of polypoidal lesions on ICGA was significantly better with PDT alone, and PDT plus ranibizumab, than with ranibizumab monotherapy [7].”
InfluentialLiang, I.-C., Lin, Y.-R., Chien, H., & Liu, K.-R. (2016) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2015.0150 · Cited by 5
“The EVEREST trial demonstrated that vPDT alone or in combination with intravitreal ranibizumab (IVR) was superior to IVR monotherapy for achieving polyp regression.(10) In 2013, the international guidelines for clinical diagnosis and treatment of PCV published by Koh et al.”
Age-related macular degeneration: is polypoidal choroidal vasculopathy recognized and treated?
Chen, Y. N., Devenyi, R. G., Brent, M. H., Kertes, P. J., Eng, K. T., Schwartz, C. E., Kohly, R. P., Chow, D. R., Wong, D. T., Berger, A. R., et al. (2017) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2017.02.014 · Cited by 6
AMD2000 study group, Akagi-Kurashige, Y., Tsujikawa, A., Yuzawa, M., Ishibashi, T., Nakanishi, H., Nakatani, E., Teramukai, S., Fukushima, M., & Yoshimura, N. (2017) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-017-0554-5 · Cited by 6
Actualisations de la Fédération France Macula : prise en charge thérapeutique de la DMLA exsudative
Tick, S., Cornut, P., Bats, F. D., Wolf, B., Souied, E. H., & Cohen, S. Y. (2018) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2018.06.002 · Cited by 6
Chhablani, J. K., Singh, S., Sahoo, N. K., & Goud, N. (2019) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_638_18 · Cited by 6
Yang, J., Yuan, M., Xia, S., & Chen, Y. (2019) · Journal of Ophthalmology · doi:10.1155/2019/1609717 · Cited by 7
Shen, Y.-S., & Cheng, C. (2020) · European Journal of Ophthalmology · doi:10.1177/1120672120913012 · Cited by 8
Liu, S., & Chhabra, R. (2021) · Eye · doi:10.1038/s41433-021-01773-x · Cited by 6
Ma, I.-H., Hsia, Y., Hsieh, Y., Ho, T., Lai, T., Yang, C., & Yang, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-99634-w · Cited by 6
Self-citationFukuyama, H., Komuku, Y., Araki, T., & Gomi, F. (2021) · Retina · doi:10.1097/iae.0000000000003395 · Cited by 6
Polypoidal Choroidal Vasculopathy
Cheung, J. C.-H., Ng, D. S., & Lai, T. Y. Y. (2020) · Retina atlas · doi:10.1007/978-981-15-3001-2_3 · Cited by 6
Self-citationPolypoidal choroidal vasculopathy: In-depth insights and promising future directions
Yang, Z., Zhang, W., Gu, X., Zhao, X., Sadda, S. R., Cheung, C. M. G., Koh, A., Loewenstein, A., Li, B., Wang, C., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101414 · Cited by 6
Self-citationChinese Guideline on the Management of Polypoidal Choroidal Vasculopathy (2022)
Chen, Y., Zhang, Y., Chen, C., Dai, H., Li, S., Ma, X., Sun, X., Tang, S., Wang, Y.-S., Wei, W., et al. (2023) · Chinese Medical Sciences Journal · doi:10.24920/004213 · Cited by 7
Chaikitmongkol, V., Tadadoltip, W., Patikulsila, D., Srisomboon, T., Narongchai, C., Choovuthayakorn, J., Watanachai, N., Kunavisarut, P., Sangkaew, A., Upaphong, P., et al. (2025) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2025.100176 · Cited by 5
Differenzialdiagnose und Therapie von Pigmentepithelabhebungen
Gamulescu, M., Helbig, H., & Wachtlin, J. (2014) · Der Ophthalmologe · doi:10.1007/s00347-013-3005-9 · Cited by 5
The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review
Wang, Y., Shen, M., Cheng, J.-W., Sun, X., & Kaiser, P. K. (2020) · Journal of Ophthalmology · doi:10.1155/2020/4924053 · Cited by 5
Saito, M., Iida, T., Kano, M., & Itagaki, K. (2013) · Eye · doi:10.1038/eye.2013.114 · Cited by 5
Sudhalkar, A. A., Balakrishnan, D., Jalali, S., & Narayanan, R. (2015) · Saudi Journal of Ophthalmology · doi:10.1016/j.sjopt.2015.08.001 · Cited by 6
“The EVEREST trial showed that photodynamic therapy, alone or combined with anti-VEGF therapy was better than antiVEGF monotherapy alone.(6) Argon laser photocoagulation has also been attempted successfully in effecting the closure of polyps.”
BackgroundCalvo-González, C., Reche-Frutos, J., Fernández‐Vigo, J. I., Donate-López, J., Serrano‐García, I., & Fernández, C. (2019) · International Ophthalmology · doi:10.1007/s10792-019-01082-z · Cited by 5
Nishimura, T., Machida, S., & Hara, Y. (2020) · Documenta Ophthalmologica · doi:10.1007/s10633-020-09758-z · Cited by 6
Li, M.-S., & Tsen, C.-L. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279778 · Cited by 5
Treatment Outcomes in Patients with Polypoidal Choroidal Vasculopathy
Muslubaş, I. S., Hocaoğlu, M., Arf, S., Özdemir, H., & Karaçorlu, M. (2016) · Turkish Journal of Ophthalmology · doi:10.4274/tjo.19981 · Cited by 6
Iesato, Y., Tanaka, M., Murata, M., Kitahara, J., Hirano, T., Kurenuma, T., Yoshida, N., & Murata, T. (2018) · BMC Ophthalmology · doi:10.1186/s12886-018-0952-6 · Cited by 5
“However, anti-VEGF therapy using ranibizumab or bevacizumab has a limited effect on PCV, with polyp regression rates ranging from 26 to 33% over a period of 1 year [12, 13].”
BackgroundSayanagi, K., Hara, C., Fukushima, Y., Sato, S., Sakaguchi, H., & Nishida, K. (2019) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2019.100485 · Cited by 5
Freund, K. B., Mrejen, S., & Gallego‐Pinazo, R. (2013) · Current Ophthalmology Reports · doi:10.1007/s40135-013-0034-0 · Cited by 5
“In the EVEREST Study, although no difference was seen in visual outcomes, verteporfin PDT combined with anti-VEGF therapy achieved a higher rate of polyp closure when compared to anti-VEGF monotherapy [40].”
Background25th RCOphth Congress, President's Session paper: 25 years of progress in medical retina
Gibson, J. M. (2014) · Eye · doi:10.1038/eye.2014.141 · Cited by 5
Laser-induced histopathological changes to the retina: A review
Gowda, A., Wood, J. P. M., Chidlow, G., & Casson, R. J. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.08.002 · Cited by 4
Tracing global progress: two decades of age-related macular degeneration research
Yuan, L., Li, L., Yuan, X., & 苑晓勇 (2025) · International Journal of Ophthalmology · doi:10.18240/ijo.2025.05.20 · Cited by 4
“The late 1990s saw the introduction of photodynamic therapy (PDT) with verteporfin, which offered improved outcomes for subfoveal CNV [35] .”
Kim, M. H., Chung, Y.-R., & Song, J. H. (2021) · BMC Ophthalmology · doi:10.1186/s12886-021-01867-w · Cited by 4
PHOTODYNAMIC THERAPY FOR THE TREATMENT OF CHOROIDAL METASTASES
Nguyen, M. T., & Stacey, A. W. (2022) · Retina · doi:10.1097/iae.0000000000003433 · Cited by 4
Miyakubo, T., Mukai, R., Matsumoto, H., Morimoto, M., Takahashi, M., Nagai, K., Nakamura, K., Hoshino, J., & Akiyama, H. (2023) · Clinical ophthalmology · doi:10.2147/opth.s386222 · Cited by 4
Wang, Y., Gu, X., & Chen, Y. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1221846 · Cited by 5
Mihalache, A., Hatamnejad, A., Patil, N. S., Popovic, M. M., Muni, R. H., Kertes, P. J., & Wong, D. T. (2023) · Ophthalmologica · doi:10.1159/000533529 · Cited by 6
Salvo, G. D., Thulasidharan, S., Barbara, R., Penwarden, A., Aggarwal, N., & Frisina, R. (2024) · Eye · doi:10.1038/s41433-024-03221-y · Cited by 4
“✉ email: gabrielladesalvo@gmail.com by the EVEREST study group [5, 6] and the Japanese Study Group of PCV [7].”
Wongchaisuwat, N., Wang, J., Hormel, T. T., Jia, Y., White, E. S., Rodanant, N., & Phasukkijwatana, N. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.1.9 · Cited by 4
Tsai, C.-L., Hsu, H., Wu, X.-C., Chen, S., & Lin, W.-Y. (2016) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2016.2538265 · Cited by 4
Self-citationKwon, J. M., Pak, K. Y., Lee, J. J., Sagong, M., & Kim, H. W. (2020) · Korean Journal of Ophthalmology · doi:10.3341/kjo.2020.0096 · Cited by 4
“In the EVEREST study comparing the efficacy of PDT monotherapy, ranibizumab monotherapy, and a PDT/ranibizumab combination therapy, the combination therapy and PDT monotherapy were superior to ranibizumab monotherapy in achieving complete regression of polyps at 6 months and 12 months, and improvement in BCVA at 12 mo…”
MethodSelf-citationWang, Y., Xie, M., Zhang, M., Zhao, X., Zhu, X., Wang, Y., Chen, Y., Chen, J., & Sun, X. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.785126 · Cited by 6
Metadata
- Authors
- Koh, A., Lee, W. K., Chen, L.-J., Chen, S.-J., Hashad, Y., Kim, H., Lai, T. Y., Pilz, S., Ruamviboonsuk, P., Tokaji, E., Weisberger, A., & Lim, T. H.
- Affiliations
- Eye & Retina Surgeons (SG)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Mackay Memorial Hospital (TW)
- Taipei Veterans General Hospital (TW)
- National Yang Ming University (TW)
- Corresponding author
- Koh, Adrian
- Hashad, Yehia
- Weisberger, Annemarie
- ORCID
- Venue
- Retina
- Published
- 2012-09
- Volume
- 32
- Issue
- 8
- Pages
- 1453-1464
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W1976433015
- Cited by
- 587
- References
- 30
- Citations by year
- 2026: 21 · 2025: 39 · 2024: 32 · 2023: 20 · 2022: 31 · 2021: 54 · 2020: 46 · 2019: 40 · 2018: 50 · 2017: 63 · 2016: 52 · 2015: 51 · 2014: 39 · 2013: 41 · 2012: 8
- FWCI
- 41.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Retina (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
- Keywords
- verteporfin photodynamic therapy, ranibizumab, combination therapy, polyp regression, best-corrected visual acuity, anti-VEGF therapy, EVEREST trial
- MeSH terms
- Ranibizumab, Verteporfin, Aged, Choroid, Combined Modality Therapy, Double-Blind Method, Coloring Agents, Female, Fluorescein Angiography, Humans, Indocyanine Green, Male, Middle Aged, Photochemotherapy, Polyps, Porphyrins, Visual Acuity, Choroid Diseases, Treatment Outcome, Photosensitizing Agents, Angiogenesis Inhibitors, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.